Prostate cancer Cancer Malignant neoplasm of prostate
Conditions
Interventions
Randomised controlled trial
Sponsors
Department of Health
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: All patients who are to have a transrectal ultrasound (TRUS) biopsy (on a Thursday) to confirm prostate cancer, with an intermediate PSA level (10-19 ng/ml), will be eligible for entry to the study. On average 8 patients undergo TRUS biopsy at Cookridge Hospital per week (divided between Tuesday and Thursday morning sessions). One MRI slot per week (Thursday morning) will be available for the study. All consenting patients will be randomised and one selected for the MRI cohort and all others will form the non-MRI cohort. Assuming at least 2 patients are recruited a week (50%) recruitment rate) the two cohorts (61 patients in each) will be recruited in 61 weeks.
Exclusion criteria
Exclusion criteria: 1. Unwilling/unable to give informed consent 2. Significant claustrophobia 3. Contra indications to MRI: pacemaker, aneurysm clips, metallic foreign bodies in the eye
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with at least one positive biopsy in each cohort | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed